Scott Mintzer

3.5k total citations
65 papers, 2.4k citations indexed

About

Scott Mintzer is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Scott Mintzer has authored 65 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Psychiatry and Mental health, 49 papers in Pediatrics, Perinatology and Child Health and 13 papers in Cellular and Molecular Neuroscience. Recurrent topics in Scott Mintzer's work include Epilepsy research and treatment (50 papers), Pharmacological Effects and Toxicity Studies (43 papers) and Neuroscience and Neuropharmacology Research (12 papers). Scott Mintzer is often cited by papers focused on Epilepsy research and treatment (50 papers), Pharmacological Effects and Toxicity Studies (43 papers) and Neuroscience and Neuropharmacology Research (12 papers). Scott Mintzer collaborates with scholars based in United States, Germany and Australia. Scott Mintzer's co-authors include Michael R. Sperling, Christopher Skidmore, Maromi Nei, Ashwini Sharan, Barry E. Gidal, Charles J. Vecht, Dieter Schmidt, Alison Pack, Martin J. Brodie and Inna Chervoneva and has published in prestigious journals such as Gastroenterology, Neurology and Annals of Neurology.

In The Last Decade

Scott Mintzer

63 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Mintzer United States 25 1.7k 1.4k 514 271 218 65 2.4k
Zhibin Chen Australia 25 1.5k 0.9× 988 0.7× 739 1.4× 366 1.4× 165 0.8× 168 2.9k
Anne Sabers Denmark 29 2.0k 1.2× 2.1k 1.6× 310 0.6× 277 1.0× 152 0.7× 80 3.0k
John A. Messenheimer United States 33 2.5k 1.5× 2.2k 1.7× 703 1.4× 414 1.5× 322 1.5× 87 3.8k
Eylert Brodtkorb Norway 35 1.9k 1.1× 1.5k 1.1× 740 1.4× 275 1.0× 175 0.8× 132 3.5k
Thomas R. Browne United States 23 1.9k 1.2× 1.7k 1.2× 836 1.6× 251 0.9× 273 1.3× 61 3.0k
Alan J. Wilensky United States 30 2.0k 1.2× 1.6k 1.2× 699 1.4× 361 1.3× 209 1.0× 61 3.1k
D. Schmidt Germany 26 1.7k 1.0× 1.3k 1.0× 788 1.5× 156 0.6× 236 1.1× 75 2.4k
Anna Rosati Italy 26 933 0.6× 725 0.5× 442 0.9× 137 0.5× 245 1.1× 74 1.8k
William E. Rosenfeld United States 30 2.3k 1.4× 1.9k 1.4× 1.2k 2.3× 257 0.9× 254 1.2× 87 2.8k
Rajiv Mohanraj United Kingdom 23 1.6k 1.0× 1.2k 0.9× 665 1.3× 226 0.8× 273 1.3× 49 2.0k

Countries citing papers authored by Scott Mintzer

Since Specialization
Citations

This map shows the geographic impact of Scott Mintzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Mintzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Mintzer more than expected).

Fields of papers citing papers by Scott Mintzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Mintzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Mintzer. The network helps show where Scott Mintzer may publish in the future.

Co-authorship network of co-authors of Scott Mintzer

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Mintzer. A scholar is included among the top collaborators of Scott Mintzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Mintzer. Scott Mintzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Terman, Samuel W., Carole E. Aubert, Chloé E. Hill, et al.. (2021). Cardiovascular disease risk, awareness, and treatment in people with epilepsy. Epilepsy & Behavior. 117. 107878–107878. 24 indexed citations
2.
Devlin, Kathryn N., Joseph I. Tracy, Maromi Nei, et al.. (2020). Consequences of mesial temporal sparing temporal lobe surgery in medically refractory epilepsy. Epilepsy & Behavior. 115. 107642–107642. 2 indexed citations
3.
Mintzer, Scott, et al.. (2019). Markers of bone and lipid metabolism with eslicarbazepine acetate monotherapy. Epilepsy Research. 158. 106216–106216. 5 indexed citations
4.
Dalakas, Marinos C., et al.. (2019). A Report on LGI1 Encephalitis in association with Squamous Cell Carcinoma of the Lung (P2.2-028). Neurology. 92(15_supplement).
5.
Gidal, Barry E., et al.. (2017). Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. Epilepsy Research. 135. 64–70. 7 indexed citations
6.
Kang, Joon Y. & Scott Mintzer. (2016). Driving and Epilepsy: a Review of Important Issues. Current Neurology and Neuroscience Reports. 16(9). 80–80. 25 indexed citations
7.
Nei, Maromi, Scott Mintzer, Christopher Skidmore, Michael R. Sperling, & Reginald T. Ho. (2016). Heart rate and blood pressure in sudden unexpected death in epilepsy (SUDEP). Epilepsy Research. 122. 44–46. 17 indexed citations
8.
Mintzer, Scott, Rachael Miller, Krunal Shah, et al.. (2016). Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. Epilepsy & Behavior. 58. 127–132. 30 indexed citations
9.
Caudle, Kelly E., Allan E. Rettie, Michelle Whirl‐Carrillo, et al.. (2014). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.. The Medicine Forum. 96(5). 542. 6 indexed citations
10.
Mintzer, Scott, Vittorio Maio, & Kathleen A. Foley. (2014). Use of antiepileptic drugs and lipid-lowering agents in the United States. Epilepsy & Behavior. 34. 105–108. 15 indexed citations
11.
Mintzer, Scott, et al.. (2013). Carbamazepine treatment of generalized tonic–clonic seizures in idiopathic generalized epilepsy. Seizure. 23(3). 234–236. 15 indexed citations
12.
Brodie, Martin J., Scott Mintzer, Alison Pack, et al.. (2012). Enzyme induction with antiepileptic drugs: Cause for concern?. Epilepsia. 54(1). 11–27. 284 indexed citations
13.
Mintzer, Scott, Christopher Skidmore, & Michael R. Sperling. (2012). B-Vitamin deficiency in patients treated with antiepileptic drugs. Epilepsy & Behavior. 24(3). 341–344. 26 indexed citations
14.
Sperling, Michael R., Christopher Skidmore, Maromi Nei, et al.. (2011). Surgical outcome in PET‐positive, MRI‐negative patients with temporal lobe epilepsy. Epilepsia. 53(2). 342–348. 118 indexed citations
15.
Mintzer, Scott, et al.. (2011). Conversion from enzyme-inducing antiepileptic drugs to topiramate: Effects on lipids and c-reactive protein. Epilepsy Research. 98(1). 88–93. 25 indexed citations
16.
Mintzer, Scott. (2010). Metabolic consequences of antiepileptic drugs. Current Opinion in Neurology. 23(2). 164–169. 79 indexed citations
17.
Mintzer, Scott, et al.. (2009). Should enzyme‐inducing antiepileptic drugs be considered first‐line agents?. Epilepsia. 50(s8). 42–50. 51 indexed citations
18.
Mintzer, Scott, et al.. (2009). Effects of antiepileptic drugs on lipids, homocysteine, and C‐reactive protein. Annals of Neurology. 65(4). 448–456. 168 indexed citations
19.
Mintzer, Scott & Michael R. Sperling. (2008). When should a resection sparing mesial structures be considered for temporal lobe epilepsy?. Epilepsy & Behavior. 13(1). 7–11. 15 indexed citations
20.
Sperling, Michael R., Maromi Nei, Andro Zangaladze, et al.. (2007). Prognosis after late relapse following epilepsy surgery. Epilepsy Research. 78(1). 77–81. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhibin Chen Breakdown of academic impact, for papers by Anne Sabers Breakdown of academic impact, for papers by John A. Messenheimer Breakdown of academic impact, for papers by Eylert Brodtkorb Breakdown of academic impact, for papers by Thomas R. Browne Breakdown of academic impact, for papers by Alan J. Wilensky Breakdown of academic impact, for papers by D. Schmidt Breakdown of academic impact, for papers by Anna Rosati Breakdown of academic impact, for papers by William E. Rosenfeld Breakdown of academic impact, for papers by Rajiv Mohanraj
Rankless by CCL
2026